BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1616 related articles for article (PubMed ID: 17951308)

  • 21. Renal function at the time of renal biopsy as a predictor of prognosis in patients with primary AL-type amyloidosis.
    Osawa Y; Kawamura K; Kondo D; Imai N; Ueno M; Nishi S; Iino N; Okada M; Suzuki Y; Hoshino S; Yamazaki H; Kishimoto H; Shimada H; Yamagishi T; Ishiyama T; Narita I; Gejyo F
    Clin Exp Nephrol; 2004 Jun; 8(2):127-33. PubMed ID: 15235929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal involvement in systemic amyloidosis.
    Browning M; Banks R; Tribe C; Bacon P; Hollingworth P; Kingswood C; Poulding J; Harrison P; Mackenzie JC
    Proc Eur Dial Transplant Assoc; 1983; 20():595-602. PubMed ID: 6657678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is the current treatment of primary and secondary amyloidosis effective?].
    Rysavá R; Spicka I; Merta M; Tesar V; Trnĕný M
    Cas Lek Cesk; 2003; 142(6):370-2. PubMed ID: 12924037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
    Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
    Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloidosis and cardiac involvement.
    Cacoub P; Axler O; De Zuttere D; Hausfater P; Amoura Z; Walter S; Wechsler B; Godeau P; Piette JC
    Ann Med Interne (Paris); 2000 Dec; 151(8):611-7. PubMed ID: 11173703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
    Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
    Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary systemic amyloidosis: response and survival in 64 patients.
    Gertz MA; Kyle RA
    Medicine (Baltimore); 1991 Jul; 70(4):246-56. PubMed ID: 2067409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever.
    Sahin S; Sahin GM; Ergin H; Kantarci G
    Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response.
    Verine J; Mourad N; Desseaux K; Vanhille P; Noël LH; Beaufils H; Grateau G; Janin A; Droz D
    Hum Pathol; 2007 Dec; 38(12):1798-809. PubMed ID: 17714761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
    Gertz MA; Lacy MQ; Gastineau DA; Inwards DJ; Chen MG; Tefferi A; Kyle RA; Litzow MR
    Bone Marrow Transplant; 2000 Nov; 26(9):963-9. PubMed ID: 11100275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.
    Levin A; Djurdjev O; Beaulieu M; Er L
    Am J Kidney Dis; 2008 Oct; 52(4):661-71. PubMed ID: 18805347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis.
    Uda H; Yokota A; Kobayashi K; Miyake T; Fushimi H; Maeda A; Saiki O
    J Rheumatol; 2006 Aug; 33(8):1482-7. PubMed ID: 16881107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis.
    Bollée G; Guery B; Joly D; Snanoudj R; Terrier B; Allouache M; Mercadal L; Peraldi MN; Viron B; Fumeron C; Elie C; Fakhouri F
    Clin J Am Soc Nephrol; 2008 Mar; 3(2):375-81. PubMed ID: 18184882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Influence of early or late referral to nephrologist over morbidity and mortality in hemodialysis].
    Gallego E; López A; Lorenzo I; López E; Llamas F; Illescas ML; Andrés E; Serrano A; Olivas E; Gómez Roldán C
    Nefrologia; 2003; 23(3):234-42. PubMed ID: 12891938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical course and prognostic factors in lupus nephropathy].
    Gamba G; Quintanilla L; del Bosque MD; Chew-Wong A; Correa-Rotter R
    Rev Invest Clin; 2000; 52(4):397-405. PubMed ID: 11061101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.